These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3285046)

  • 1. Treatment of steroid-resistant acute graft-vs-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin.
    Kernan NA; Byers V; Scannon PJ; Mischak RP; Brochstein J; Flomenberg N; Dupont B; O'Reilly RJ
    JAMA; 1988 Jun; 259(21):3154-7. PubMed ID: 3285046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid-resistant acute graft-versus-host disease.
    Byers VS; Henslee PJ; Kernan NA; Blazar BR; Gingrich R; Phillips GL; LeMaistre CF; Gilliland G; Antin JH; Martin P
    Blood; 1990 Apr; 75(7):1426-32. PubMed ID: 2180494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
    Przepiorka D; Chan KW; Champlin RE; Culbert SJ; Petropoulos D; Ippoliti C; Khouri I; Huh YO; Vreisendorp H; Deisseroth AB
    Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation.
    Martin PJ; Nelson BJ; Appelbaum FR; Anasetti C; Deeg HJ; Hansen JA; McDonald GB; Nash RA; Sullivan KM; Witherspoon RP; Scannon PJ; Friedmann N; Storb R
    Blood; 1996 Aug; 88(3):824-30. PubMed ID: 8704237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier.
    Vallera DA; Carroll SF; Snover DC; Carlson GJ; Blazar BR
    Blood; 1991 Jan; 77(1):182-94. PubMed ID: 1984794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
    Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation.
    Przepiorka D; LeMaistre CF; Huh YO; Luna M; Saria EA; Brown CT; Champlin RE
    Ther Immunol; 1994 Apr; 1(2):77-82. PubMed ID: 7584486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy for ongoing graft-versus-host disease induced across the major or minor histocompatibility barrier in mice with anti-CD3F(ab')2-ricin toxin A chain immunotoxin.
    Vallera DA; Taylor PA; Panoskaltsis-Mortari A; Blazar BR
    Blood; 1995 Dec; 86(11):4367-75. PubMed ID: 7492798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host disease.
    Fauser AA; Shustik C; Langleben A; Laurent G; Kanz L; Spurll GM; Price G; Ahlgren PD; Cooper BA
    Clin Invest Med; 1988 Feb; 11(1):40-6. PubMed ID: 3284672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation.
    Martin PJ; Pei J; Gooley T; Anasetti C; Appelbaum FR; Deeg J; Hansen JA; Nash RA; Petersdorf EW; Storb R; Ghetie V; Schindler J; Vitetta ES
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):552-60. PubMed ID: 15282533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application considered for immunotoxin in treatment of graft-vs-host disease.
    Skolnick A
    JAMA; 1991 Apr; 265(16):2041-2. PubMed ID: 2013915
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.
    Herbelin C; Stephan JL; Donadieu J; Le Deist F; Racadot E; Wijdenes J; Fischer A
    Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
    Antin JH; Bierer BE; Smith BR; Guinan EC; Provost MM; Ferrara J; Macklis RM; Tarbell NJ; Blythman H; Bouloux C
    Prog Clin Biol Res; 1990; 333():207-15. PubMed ID: 1689852
    [No Abstract]   [Full Text] [Related]  

  • 15. Rationale for clinical use of immunotoxins in cancer and autoimmune disease.
    Byers VS; Baldwin RW
    Semin Cell Biol; 1991 Feb; 2(1):59-70. PubMed ID: 1954344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
    Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
    Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors.
    Krance R; Heslop HE; Mahmoud H; Ribeiro R; Douglass E; Hurwitz C; Santana V; Kun L; Horowitz MM; Brenner MK
    Bone Marrow Transplant; 1993 Jan; 11(1):33-6. PubMed ID: 8431709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant.
    Henslee-Downey PJ; Parrish RS; MacDonald JS; Romond EH; Marciniak E; Coffey C; Ciocci G; Thompson JS
    Transplantation; 1996 Mar; 61(5):738-45. PubMed ID: 8607177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease.
    Martin PJ; Hansen JA; Torok-Storb B; Moretti L; Press O; Storb R; Thomas ED; Weiden PL; Vitetta ES
    Bone Marrow Transplant; 1988 Sep; 3(5):437-44. PubMed ID: 2973360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation. The correlation between residual CD5 negative T cells and subsequent graft-versus-host disease.
    Filipovich AH; Vallera D; McGlave P; Polich D; Gajl-Peczalska K; Haake R; Lasky L; Blazar B; Ramsay NK; Kersey J
    Transplantation; 1990 Sep; 50(3):410-5. PubMed ID: 1698319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.